anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Introduction: Urologic complications are thought to be the most common surgical complication of renal transplantation. Ureteral pathology, including stenosis, urine leak, and vesicoureteral reflux, predominates. Although endourologic and interventional radiological management may be utilized, failure rates remain relatively high and surgical reconstruction remains the definitive management. Robotic ureteral reconstruction has been demonstrated to provide patient benefit in nontransplant populations, but the literature on transplant reconstruction is very limited. This study reports an additional series of patients with a focus on surgical technique, as well as reviews the available evidence for robotic reconstruction for post-transplant ureteral complications. Methods: All institutional patients undergoing robotic-assisted reconstruction for post-transplant ureteral complications for the years 2019-2022 were included. Intra- and postoperative variables, patient demographics, and follow-up data were obtained retrospectively from parsing of patient records. Statistics were tabulated descriptively. Results: Eleven patients underwent ureteral reconstruction. Of the 11, 9 (81%) were male with a mean age of 51.9 years (16-70) and BMI of 33.8 (24.3-49.1). The most common (10/11) indication for reconstruction was stricture; the most common (10/11) technique used was Lich-Gregoir reimplantation. Mean operative time was 288 minutes (143-500). There were no intra- or immediate postoperative complications. Median length of stay was 2 days (1-22). There were two incidences of mortality at 2 and 5 months postoperatively unrelated to surgery. There were four readmissions within 30 days, three for urinary tract infection (UTI) and one for a pelvic abscess which required washout. The remainder of the cohort has been followed for a mean of 14.6 months (6-41) without any incidences of graft loss or recurrence of ureteral pathology. Conclusions: Robotic-assisted ureteral reconstruction is a technically challenging but highly feasible technique that may provide the benefits of minimally invasive surgery while still allowing definitive reconstruction. Centers with extensive robotic capabilities should consider the technique.
Immunoglobulin A nephropathy (IgAN) is the most common glomerular disease, leading to chronic kidney disease. The disease is characterized by microscopic hematuria, gross episodic hematuria, hypertension, and subnephrotic proteinuria with or without renal function impairment. It affects individuals of all age groups, commonly seen in 10-40 years of age. It is progressive in nature and leads to chronic kidney disease, necessitating renal replacement therapy. This case series of in a tertiary care hospital in Western India highlights the presentation of this disease in young adults, its aggressive course, its rapid progression, and its early recurrence in the posttransplant period. It also summarizes the treatment recommendations for IgA recurrence in kidney recipients. The disease is known to have a high chance of posttransplant recurrence. Optimizing renin-angiotensin-aldosterone system (RAAS) blockade, blood pressure control, and increasing immunosuppression in rapidly deteriorating cases are the strategies recommended to treat IgA recurrence in kidney transplant recipients.
Dynamic antral contraction scintigraphy (DACS) has been used to evaluate for gastric dysmotility by measuring antral contraction frequency and ejection fraction (EF). Fourier phase image analysis has the potential to assess gastric antral contractions for dyssynchrony as has been used for analyzing nuclear cardiology ventriculography (multigated acquisition studies) for cardiac dyssynchrony. The aims of this study were to determine whether Fourier phase analysis helps to characterize antral motility physiology, whether Fourier phase analysis correlates with conventional gastric emptying scintigraphy (GES), and which DACS parameters may aid in diagnosing gastric dysmotility, particularly delayed gastric emptying (GE). Methods: DACS and GES of healthy volunteers (n = 22) were compared with patients (n = 99) with symptoms of gastroparesis. New DACS Fourier phase analysis software was developed. Results: GE was delayed (n = 53) or normal (n = 46) in patients. There was a linear correlation between the time for the stomach to empty 50% of the meal and the percentage total proximal and distal in-phase antral pixels at 30 min (r = 0.37, P = 0.0001) and 60 min (r = 0.26, P = 0.007). In healthy volunteers, the mean proximal-to-distal ratio of in-phase antral pixels increased from 1.67 (30 min) to 2.65 (120 min) (P = 0.035), and EF increased from 23% (30 min) to 32% (120 min) (P = 0.022). Multivariable regressions of percentage total proximal and distal in-phase antral pixels (30 min) and EF (60 min) were the best predictors of abnormal GE (adjusted odds ratio, 3.30 [95% CI, 1.21-9.00] and 2.97 [95% CI, 1.08-8.21], respectively). Conclusion: This study used Fourier phase analysis to analyze DACS in healthy volunteers and patients with symptoms of gastroparesis. In addition to establishing reference values, new physiologic information on antral motility was obtained. In healthy volunteers, there was an increasing proximal-to-distal ratio of in-phase antral pixels and antral EF over time after meal ingestion. The percentage total proximal and distal in-phase antral pixels at both 30 and 60 min correlated well with GE values for the time for the stomach to empty 50% of the meal. For symptomatic patients, the percentage total proximal and distal in-phase antral pixels at 30 min and the EF at 60 min after meal ingestion correlated with delayed GE on conventional GES. Thus, Fourier phase analysis of DACS appears to have potential to further aid in diagnosing gastric dysmotility in GES.
<P>PROBLEM TO BE SOLVED: To provide method for screening, classifying, ranking antibodies, based on epitope recognition properties and binding affinity, and evaluating the antibodies ranked to determine whether the antibody is useful for cure product, in identifying antibodies which are useful in a therapeutic product.  <P>SOLUTION: This method (i) clarifies the potential utility in therapy of protein targets, relative to molecules interacting with these protein targets, while (ii) interacts with those protein targets to identify, such a molecule as achieving utility in therapy. In this method, protein targets are screened for a plurality of molecules to find interactive ones among them. Those interactive molecules are classified in accordance with predefined standards for selecting representative members to be used for preselected assay, including these protein targets. Interactions verified in assay are recorded and analyzed.  <P>COPYRIGHT: (C)2007,JPO&INPIT
1,195,666. Valepotriates. KALI-CHEMIE A.G. 11 March, 1969 [30 March, 1968], No. 12635/69. Heading C2C. Novel compounds I and II in which R 1  and R 2  each represent an isopropyl or isobutyl radical and the corresponding 5,6- dihydro compounds of Formula I are prepared by extraction of roots and rhizomes of the species Valeriana mexicana, Valeriana toluccana D.C. or Valeriana wallichii D.C. below 30‹ C. with lipophilic solvents in the presence of C 2-7  aliphatic carboxylic acids at a pH of 3-7, if desired with addition of alkali metal or ammonium salts of these carboxylic acids as buffers and working up the extract.
Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
A method of detecting osteoporosis in a mammalian is disclosed herein which includes: a) obtaining a sample of a bone related tissue or cells; and b) measuring the concentration of at least a marker which is either bacteria, bacteria produced factors, or HSPs. The method may further include comparing the concentration with concentrations from the same individual over a period of time or against a standard concentration. The marker may be a bacteria, a chaperone molecule, or a bacteria produced. The method may include a first assay and a second assay over a period for example of at least about 12 hours. The concentration of HSP can be measured using an immunoassay. The assay may use a nucleotide molecule encoding HSP. Also provided herein is a method of treating or preventing osteoporosis caused by a bone disease which includes administering to a mammalian subject a therapeutically effective amount of a formulation which is either an HSP antigenic formulation or a bacterial antigenic formulation.
Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
INTRODUCTION: The number of cancer patients receiving long-term hemodialysis (HD) is increasing, and HD could jeopardize treatments' safety and efficacy. Therefore, managing anticancer drugs is critical in this frail population. In addition, evidence of HD safety or risk is regularly released both for cytotoxic chemotherapy (CT) or hormone therapy (HT) as well as new therapies with molecularly targeted therapies (MTT), immune checkpoint inhibitors (ICI), and a summary of current knowledge is needed.
METHODS: We aimed to synthesize available data on cancer treatments in HD patients using PubMed database, FDA labels, summary of product characteristics (SmPC), FDA and EMA approval documents, guidelines and finally case reports for which relevant pharmacokinetic (PK) data is available.
RESULTS: For CT, recently proposed guidelines were balanced by the publication of particular toxic reports following them. SmPC was helpful in some cases, but no data was found for most CTs. MTT, both oral and monoclonal antibodies, were rarely modified by HD. However, HD patients have particular frailty that could require dose adaptation despite no substantial PK modification. Similarly, exposure to ICIs is unlikely to be modified by HD since immunoglobulins are not dialyzable. For HT, PK characteristics and HD impact were more heterogeneous and were reviewed molecule by molecule.
CONCLUSIONS: We summarized current knowledge on HD and cancer treatments. Data remains scarce, and the latest guidelines rely on few clinical data. There is a need to collect both retrospective and prospective data to better characterize the safety and relevant dose and schedule adaptations whenever needed in this situation to reinforce future guidelines.
Inclusion criteria were to be between 18-65 years of age, to volunteer to participate in the study, to have Stage I-III breast cancer, to have at least 15 months after breast cancer surgery, to have six months after active breast cancer treatment (i.e. surgery/chemotherapy), to have no problems in reading and/or understanding the scales and to be able to cooperate with the tests. Exclusion criteria were the presence of active infection, musculoskeletal and neurologic disease that may affect exercise performance, symptomatic heart disease, neurologic disease or other clinical diagnosis that may affect cognitive status.
PURPOSE: This study describes chemotherapy-induced nausea and vomiting (CINV) control rates in pediatric and adult patients who did or did not receive guideline-consistent CINV prophylaxis.
METHODS: We conducted a systematic literature review of studies published in 2000 or later that evaluated CINV control in patients receiving guideline-consistent vs. guideline-inconsistent CINV prophylaxis and reported at least one CINV-related patient outcome. Studies were excluded if the guideline evaluated was not publicly available or not developed by a professional organization. Over-prophylaxis was defined as antiemetic use recommended for a higher level of chemotherapy emetogenicity than a patient was receiving.
RESULTS: We identified 7060 citations and retrieved 141 publications for full-text evaluation. Of these, 21 publications (14 prospective and seven retrospective studies) evaluating guidelines developed by six organizations were included. The terms used to describe CINV endpoints and definition of guideline-consistent CINV prophylaxis varied among studies. Included studies either did not address over-prophylaxis in their definition of guideline-consistent CINV prophylaxis (48%; 10/21) or defined it as guideline-inconsistent (38%; 8/21) or guideline-consistent (3/21; 14%). Eleven included studies (52%; 11/21) reported a clinically meaningful improvement in at least one CINV endpoint in patients receiving guideline-consistent CINV prophylaxis. Ten reported a statistically significant improvement.
CONCLUSIONS: This evidence supports the use of guideline-consistent prophylaxis to optimize CINV control. Institutions caring for patients with cancer should systematically adapt CINV CPGs for local implementation and routinely evaluate CINV outcomes.
Supercritical impregnation of drug-active products in PLA filaments suitable for use in 3D printing. The invention comprises the production of PLA impregnated with a natural extract of Mangifera indica L. with pharmacoactive properties using supercritical technology for use as pharmacoactive implants in biomedicine. The anti-inflammatory and antioxidant properties of the impregnated PLA filament are evaluated, observing that it retains its bioactivity after 3D printing. The printed samples show lower bioactivity values, which is attributed to the fact that the extract in the printed polymer is released more slowly than in the samples before 3D printing, since the porosity of the polymer varies. If the biomedical use of the product is considered, this result is very positive since it allows the pharmacoactive effect of the extract to last longer in the case of the samples printed with the impregnated filament.  (Machine-translation by Google Translate, not legally binding)
1,182,320. Medicines comprising dihydroorotic acid salts. ED. GEISTLICH SOHNE A.G. 23 Dec., 1968 [21 Dec., 1967], No. 58140/67. Heading A5B. [Also in Division C2] Pharmaceutical compositions comprise at least one salt of dihydro-orotic acid with a primary, secondary or tertiary aliphatic amine containing at least one other hydrophilic group selected from hydroxy, esterified hydroxy, carboxy, amino or carbamoyl, in the molecule together with a pharmaceutical carrier or diluent and optionally vitamins, minerals, amino acids or enzymes. They may be administered orally, rectally, parenterally or topically and are used to improve the flow of blood through the capillaries and vascular system as well as to improve the depth of sleep, level of depression and exhaustion and alertness.
Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient. However, bleeding and ischemic risks are often present in the same patient, making it difficult to achieve this balance. The fact that oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) have diverse pharmacodynamic profiles that affect clinical outcomes supports the rationale for using platelet function and genetic testing to individualize antiplatelet treatment regimens. Indeed, up to one-third of patients treated with clopidogrel, but a minority of those treated with prasugrel or ticagrelor, exhibit high residual platelet reactivity resulting in an increased thrombotic risk. On the other hand, prasugrel and ticagrelor are frequently associated with low platelet reactivity and increased bleeding risk compared with clopidogrel without providing any additional reduction in ischemic events compared with patients who adequately respond to clopidogrel. The use of platelet function and genetic testing may allow for a guided selection of oral P2Y12 inhibitors. However, the nonuniform results of randomized controlled trials have led guidelines to provide limited recommendations on the implementation of these tests in patients undergoing percutaneous coronary intervention. In light of recent advancements in the field, this consensus document by a panel of international experts fills in the guideline gap by providing updates on the latest evidence in the field as well as recommendations for clinical practice.
PROBLEM TO BE SOLVED: To obtain the subject stable preparation easy to administrate, having excellent percutaneous absorbability by incorporating a skin contact base with a bromhexine as an expectorant in amounts within a specific range. SOLUTION: This preparation is obtained by incorporating a skin contact base with 0.5-60 (pref. 1-30) wt.% of a bromhexine and/or a pharmacologically acceptable salt thereof. The skin contact base is a tack agent having tackiness at normal temperatures, and it is recommended that a layer of the tack agent is provided on one side of a substrate; the tack agent is pref. selected from acrylic and silicone-based agents. The skin contact base may be formulated with an organic liquid ingredient such as a glycol, fatty oil, fatty acid, alcohol or fatty acid ester, affording such effects as improving skin adherability and active ingredient infiltrativity and alleviating skin irritancy.
Cowpea is a leguminous plant belonging to the fabaceae family cultivated in the North and Northeast regions of Brazil, with productive potential. Among the abiotic factors, water deficiency is one of the main environmental limitations that influence agricultural production in the world. The objective of this work was to study the relative water content and osmoregulators of cowpea plants subjected to water stress. The experiment was carried out in a greenhouse at the Universidade Federal Rural da Amazônia (UFRA, Belém, PA), cowpea plants BR-17 Gurguéia Vigna unguiculata (L.) Walp were used. The experimental design was completely randomized (DIC) in a 2 × 2 factorial scheme, two water conditions (control and water deficit) and two times of stress (four and six days of water suspension), with 7 replications, totaling 28 experimental units. The water deficit affected plants, causing a reduction in relative water content (69.98%), starch (12.84% in leaves and 23.48% in roots) and carbohydrates (84.34%), and an increase in glycine-betaine, sucrose (114.11% in leaves and 18.71% in roots) and proline (358.86%) at time 2. The relative water content was negatively affected by water conditions, with a decrease in relation to the interaction of the aerial part and the root system. Therefore, greater metabolic responses were noted in plants that were subjected to stress treatment at time 2 (6 days).
FIELD: pharmaceutical industry. SUBSTANCE: described are new benzopyrans of formula I:   wherein R 1  is phenyl, methoxyphenyl, fluorophenyl or pyridyl, trifluoromethyl phenyl; R 2  is H or C 1-5  alkyl, or C 2-5  alkylene bonded with с R 1 ; R 3  is group of formula: -N(R 9 )2COR 10  wherein R 9  is hydrogen, and R 10  is phenyl or pyridyl, or R 9  and R 10  are together 1,3-butadienylene or group of formula (CH 2 ) n , wherein n is integer of 3 to 5 inclusive; R 4  is hydrogen and R 5  is hydroxy in trans-position with respect to R 3 ; or R 4  and R 5  together are additional bond as denoted by dotted line, R 6  and R 7  are independently C 1-5  alkyl, and R 8  is hydrogen, or physiologically hydrolyzable and physiologically acceptable ester of said compound or acid addition salt or quaternary ammonium salt of said compound or ester. Also described are method of preparation thereof, intermediate compounds and pharmaceutical compositions that open K channels, broncholytic agents and agents for suppressing hyperreactivity of respiratory tract, e.g. in treating asthma. EFFECT: improved properties of the title compounds. 7 cl, 1 tbl
Hypothyroidism has been reported to be associated with chronic kidney disease (CKD). However, the impact of thyroid-stimulating hormone (TSH) on new onset of CKD and its gender dependence remain undetermined. We investigated the association of serum TSH level and the development of CKD defined by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 or positive for urine protein in 28,990 Japanese subjects who received annual health examinations. After excluding subjects with no data for serum TSH, urinalysis and eGFR and those with CKD at baseline, a total of 10,392 subjects (men/women: 6802/3590, mean age: 48 years) were recruited. During a 10-year follow-up, 1185 men (6.7%) and 578 women (2.9%) newly developed CKD. Multivariable Cox proportional hazard models after adjustment of age, body mass index, smoking habit, hypertension, diabetes mellitus, dyslipidemia, ischemic heart disease and eGFR (≥ 90 mL/min/1.73 m2) showed that the hazard ratio (HR) for the development of CKD in the high TSH (> 4.2 mU/L) group was significantly higher than that in the low TSH (≤ 4.2 mU/L) group in men (HR [95% confidence interval]: 1.41 [1.09-1.83]) but not in women (1.08 [0.77-1.51]). There was a significant interaction between sex and the category of TSH level for the development of CKD (p = 0.02). The adjusted HR with a restricted cubic spline increased with a higher level of TSH in men but not in women. In conclusion, a high level of TSH is associated with an increased risk for the development of CKD in men but not in women.
After the introduction of the gut-lung axis theory, extensive studies revealed the diversity of microbiomes among healthy smokers and COPD patients form the respiratory samples or lung tissues. In the previous study, distinct difference in composition of microbiome in lung tissue between healthy smokers and COPD patients was reported. This study is to build a microbiome cohort by collecting sputum and fecal samples every few months for three years from healthy smokers and chronic obstructive pulmonary disease (COPD) patients who are being followed up by Asan Medical Center. The aim of this study is to analyze the composition of microbiome of various samples (e.g. sputum, feces) and describe the difference between healthy smokers and COPD patients. This study would help establishing gut-lung axis model in humans.
Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain a medicine for preventing, treating and alleviating disorders or diseases related to transplantation, comprising inositol triphosphate. CONSTITUTION: This medicine is obtained by including at least one kind of isomer of inositol triphosphate (IP3 ), preparing the isomer or further mixing the isomer with a conventional additive, a vehicle, a carrier, etc., and preparing the mixture. The medicine can be prepared in the form of tablets, granules, capsules, etc., and a daily dose thereof is 0.1-1000mg IP3 /kg weight. The medicine comprises IP3 in an amount of 0.01-1.5g per unit dose. The medicine improves the function of transplanted organism and suppresses rejection. D- myoinositol-1,2,6-triphosphate is exemplified as preferred IP3 .
In some implementations, a machine learning model (e.g., a knowledge processing system) can apply a reasoning technique to knowledge representations associated with cells (e.g., using a genetic algorithm) and predict a clinical outcome (e.g., for a patient). In some implementations, a method includes producing a cell population. Gene expression data for the cell population can be received. The gene expression data can be analyzed to identify a set of gene signatures. The set of gene signatures can be provided as an input to a machine learning classifier. A predicted clinical outcome can be generated.